Seven infants with documented neonatal inclusion conjunctivitis were studied at 7 to 11 months of age. All had received topical tetracycline or sulfacetamide therapy for 10 to 14 days at the time of initial diagnosis. None had recurrence of disease or persistent clinical symptoms. At follow-up, inflammatory cells were present in conjunctival scrapings but Giemsa and indirect fluorescent antibody stains revealed no inclusions. No child had conjunctival scars but two had minimal scarring of the corneal limbus as described in previous investigations on inclusion conjunctivitis.
Goscienski PJ, Sexton RR. Follow-Up Studies in Neonatal Inclusion Conjunctivitis. Am J Dis Child. 1972;124(2):180–182. doi:10.1001/archpedi.1972.02110140030003
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: